ZOLEDRONIC ACID | N204016 | HOSPIRA INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1 | Active | Mohammed Milhem | 17 | 2017-07-18 → 2028-05-01 | |
| Phase 3 | Active | UNICANCER | 318 | 2007-03 → 2026-12 | |
| Phase 2/3 | Active | Medical Research Council | 11,992 | 2005-07-08 → 2030-12 | |
| Phase 2 | Active | University of Nebraska | 46 | 2016-09-16 → 2027-12 | |
| Phase 2 | Not Yet Recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-09-15 → 2029-12-31 | |
| Phase 4 | Not Yet Recruiting | Sahlgrenska University Hospital | 216 | 2027-01-11 → 2031-12-31 | |
| Phase 1 | Not Yet Recruiting | University of Campinas, Brazil | 24 | 2026-08-15 → 2028-08-15 | |
| Phase 3 | Recruiting | St. Louis University | 120 | 2018-05-03 → 2028-01 | |
| Phase 1/2 | Recruiting | University of Florida | 27 | 2026-02-11 → 2030-02 | |
| Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 → 2030-04-30 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
19 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Dec 21, 2018 | SUPPL -3 | View Letter (PDF) |
| Dec 30, 2015 | ORIG -1 | View Letter (PDF) |
| Jul 8, 2013 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.